

NUESTROS AUTORES

- Mezquita P, Muños M, Luna JD, et al. Relation between vitamin D insufficiency, bone density and bone metabolism in healthy postmenopausal women. *J Bone Miner Res* 2001; 16: 1408-15.
- Blay P, Fernández-Martínez JM, Díaz-López B. Vertebral involvement in hyperphosphatemic tumoral calcinosis. *Bone* 2001; 28: 316-8.
- Espallargues M, Sampietro L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature.

Se ruega a los autores enviar una copia del trabajo para incluir su cita en esta Sección.

REVISIONES

- Jerome CP, Peterson PE. Nonhuman primate models in skeletal research. *Bone* 2001; 29: 1-6.
- Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. *J Bone Miner Res* 2001; 16: 1379-87.
- Parfitt AM. The bone remodeling compartment: a circulatory function for bone lining cells. *J Bone Miner Res* 2001; 16: 1583-5.
- Melton LJ, Orwoll ES, Wasnich RD. Does bone density predict fractures comparably in men and women? *Osteoporosis Int* 2001; 12: 707-9.
- Lanyon L, Skerry T. Postmenopausal osteoporosis as a failure of bone's adaptation to functional loading: A hypothesis. *J Bone Miner Res* 2001; 16: 1937-47.
- Raisz LG, Seeman E. Causes of age-related bone loss and bone fragility: An alternative view. *J Bone Miner Res* 2001; 16: 1948-52.
- Parfitt AM. The bone remodeling compartment: A circulatory function for bone lining cells. *J Bone Miner Res* 2001; 16: 1583-5.
- Blank RD. Breaking down bone strength: a perspective on the future of skeletal genetics. *J Bone Miner Res* 2001; 16: 1206-11.
- Zaidi M, Troen B, Moogan BS, Abe E. Cathepsin K, osteoclastic resorption and osteoporosis therapy. *J Bone Miner Res* 2001; 16: 1747-9.
- Meulen MCH, Jepsen KJ, Mikic B. Understanding bone strength: Size isn't everything. *Bone* 2001; 29: 101-4.
- Rosen CJ, Beamer WG, Donahue LR. Defining the genetics of osteoporosis: Using the mouse to understand man. *Osteoporosis Int* 2001; 12: 803-10.
- Olgaard K, Lewin E. Prevention of uremic bone disease using calcimetic compounds. *Ann Rev Med* 2001; 52:203-220
- Nilsson S, Makala S, Treuer E, et al. Mechanisms of estrogen action. *Physiol Rev* 2001; 81:1536-65.

Tordoff MG. Calcium: Taste, intake and appetite. *Physiol Rev* 2001; 81: 1567-97.

OTROS ARTÍCULOS DE INTERÉS

- Wehrli FW, Gombreg BR, Saha PK, et al. Digital topological analysis of *in vivo* magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. *J Bone Miner Res* 2001; 16: 1520-31.
- Szulc P, Garnero P, Muñoz F, et al. Cross-sectional evaluation of bone metabolism in men. *J Bone Miner Res* 2001; 16: 1642-50.
- Godfrey K, Walker K, Robinson S, et al. Neonatal bone mass: Influence of parental birth weight, maternal smoking, body composition and activity during pregnancy. *J Bone Miner Res* 2001; 16: 1694-703.
- More C, Bettembuk P, Bhattoa HP, Balogh A. The effects of pregnancy and lactation on bone mineral density. *Osteoporosis Int* 2001; 12: 732-7.
- Langlois JA, Mussolino ME, Visser M, et al. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture. The NAHANES I epidemiological follow-up study. *Osteoporosis Int* 2001; 12: 763-8.
- Grainge MJ, Coupland CAC, Cliffe SJ, et al. Reproductive menstrual and menopausal factors: Which are associated with bone mineral density in early postmenopausal women? *Osteoporosis Int* 2001; 12: 788-93.
- Hubacher M, Wettstein A. Acceptance of hip protectors for hip fracture prevention in nursing homes. *Osteoporosis Int* 2001;12(9):794-9.
- Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. *Osteoporosis Int* 2001; 12: 385-90.
- Kanis JA, Dawson A, Oden A, Johnell O, de Lere C, Jonson B. Cost-effectiveness of preventing hip fracture in the general female population. *Osteoporosis Int* 2001; 12: 356-61.
- Watts NB, Harris ST, Genant HK. Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. *Osteoporosis Int* 2001; 12: 429-31.
- Van Staa TP, Leufkens HGM, Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. *Bone* 2000; 27: 563-8.
- Sato Y, Kaji M, Higuchi F, Yanagida I, Oishi K, Oizumi K. Changes in bone and calcium metabolism following hip fracture in elderly patients. *Osteoporosis Int* 2001; 12: 445-9.
- MacDonald HM, McGuigan FA, New SA, Campbell MK, Golden MHN, Ralston SH, Reid DM. Col1a1 sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss. *J Bone Miner Res* 2001; 9: 1634-41.
- Bajnok E, Takacs I, Vargha P, Speer G, Nagy Z, Lakatos P. Lack of association between interleukin-1 receptor antagonist

- protein gene polymorphism and bone mineral density in hungarian postmenopausal women. *Bone* 2001; 27: 559-62.
- Khastir G, Studd J, Holland N, Alagband-Zadeh, Sims TJ, Bailey AJ. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. *Osteoporos Int* 2001; 12: 465-70.
- Thomas T, Burguera B, Melton LJ, Atkinson EJ, O'Fallon WM. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. *Bone* 2001; 29: 114-20.
- Efstathiadou Z, Tsatsoulis A, Ioannidis JPA. Association of collagen Ia 1 Sp1 polymorphism with the risk of prevalent fractures: a meta-analysis. *J Bone Miner Res* 2001; 16: 1586-92.
- Patel S, Kwan JTC, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. *J Bone Miner Res* 2001; 16: 1863-70.
- Lauderdale DS, Thisted RA, Wen M, Favus MJ. Bone mineral density and fracture among prevalent kidney stone cases in the third national health and nutrition examination survey. *J Bone Miner Res* 2001; 16: 1893-8.
- Johansson S, Melhus H. Vitamin A antagonizes calcium response to vitamin D in man. *J Bone Miner Res* 2001; 16: 1899-905.
- Godfrey K, Walker-Bone K, Robinson S, et al. Neonatal bone mass: Influence of parental birthweight, maternal smoking, body composition and activity during pregnancy. *J Bone Miner Res* 2001; 16: 1694-703.
- Beck TJ, Stone KL, Oreskovic TL, et al. Effect of current and discontinued estrogen replacement therapy on hip structural geometry: The Study of Osteoporotic Fractures. *J Bone Miner Res* 2001; 16: 2103-10.
- Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. *J Bone Miner Res* 2001; 16: 2111-7.
- Venesmaa PK, Kroger HPJ, Miettinen HJA, et al. Alendronate reduces periprosthetic bone loss after uncemented total hip arthroplasty: a prospective randomized study. *J Bone Miner Res* 2001; 16: 2126-31.
- Heiskanen JT, Froger H, Paakkonen M, et al. Bone mineral metabolism after total gastrectomy. *Bone* 2001; 28: 123-7.
- Legrand E, Hedde C, Gallois Y, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. *Bone* 2001; 29: 990-5.
- Taylor JC, Sterkel B, Utley M, et al. Opinions and experiences in general practice on osteoporosis prevention, diagnosis and management. *Osteoporosis Int* 2001; 12: 844-8.
- Tosteson ANA, Jonsson B, Grima DT, et al. Challenges for model based economic evaluations of postmenopausal osteoporosis. *Osteoporosis Int* 2001; 12: 849-57.
- Buchs N, Helg C, Collao C, et al. Allogeneic bone marrow transplantation in associated with a preferential femoral neck bone loss. *Osteoporosis Int* 2001; 12: 880-6.

NOTICIAS

LA FUNDACIÓN HISPANA DE OSTEOPOROSIS Y ENFERMEDADES METABÓLICAS ÓSEAS

Convoca el
IX PREMIO CIENTÍFICO FHOEMO 2002
de acuerdo con las siguientes
BASES

1. Este Premio, con una dotación de 1.506,02 €, tiene como objetivo premiar al mejor trabajo sobre Osteoporosis y Enfermedades Metabólicas Óseas.
2. El trabajo, para la presente edición, deberá haber sido desarrollado en España o Iberoamérica y publicado durante el año 2000 en cualquier revista de habla hispana.
3. La fecha límite para la recepción de los trabajos será el 15 de enero de 2003.
4. El Jurado estará compuesto por cuatro miembros del Comité Científico de la FHOEMO, actuando como secretaria del Jurado, con voz pero sin voto, la Secretaria de la misma.
5. La decisión del Jurado será inapelable y el Premio podrá ser declarado desierto si, a juicio del Jurado, se estimase que los trabajos presentados no reúnen el nivel profesional médico y técnico adecuados.
6. La FHOEMO se reserva la disponibilidad del trabajo una vez publicado para su difusión, si lo considera oportuno. Los trabajos concursantes no serán devueltos a sus autores.
7. Los aspirantes aceptarán las presentes bases por el mero hecho de concurrir a esta convocatoria.
8. Las solicitudes se enviarán, junto con seis copias del trabajo objeto de consideración, a: Premio Científico PHOEMO. Gil de Santivañes, 6. 28001 Madrid.